In our study, Rg1 focused on ATG2B drastically inhibited lipid droplet formation in steatosis HepG2 cells, suggesting that Rg1 should be a doable therapeutic agent for the remedy of NASH. Here, PPP1R3A is linked to metabolic dysfunction-associated steatohepatitis.